The_FD

Bon Ninie n'arrivant pas à poster les liens qu'elle veut je lui file un coup de main, je poste à sa place.

Elle voudrait les grandes lignes (un résumé suffit) des textes suivant à caractères plutôt médicaux.
La traduction est a effectuer d'anglais vers français.

Je lui en ai déjà fait 1 mais je suis trop surbooké pour les autres.

voici les textes

http://by5fd.bay5.hotmail.msn.com/cg...domain=msn.com

http://by5fd.bay5.hotmail.msn.com/cg...domain=msn.com

http://by5fd.bay5.hotmail.msn.com/cg...domain=msn.com

voir les textes plus loins

ninie

merci à toi nico pour les avoir poster, maintenant je dois dire que je compte bcp sur vous qui allez les lire, j'ai en effet exam mercredi et je dois les présenter... voilà merci d'avanceeeuuuuuu

michelangelo

cerait t'il possible, de plutôt faire un copier coller, parceque moi j'arive pas a acceder sur les liens, a moins de devoir encore m'enregistrer sur le site!

The_FD

Voici le premier texte, je posterai les autres une fois la trad faite, vue la longueure

Abstract

Neurodegeneration occurs in the majority of the more than 40 known lysosomal storage diseases. Since the nervous system in these disorders can be globally affected, effective treatment would require persistent widespread correction. Biffi et al. show such correction is possible in a mouse model of metachromatic leukodystrophy by the transplantation of hematopoietic cells genetically modified to overexpress the missing lysosomal enzyme. The results reveal a nervous system damage-response pathway that can be harnessed to provide therapy to the nervous system in these serious disorders.

Although individual lysosomal storage diseases are rare, as a group they represent a significant fraction of severe inherited metabolic conditions (1). The more than 40 different storage disorders cumulatively affect 1 in 5,000 live births. Most of the disorders are caused by the deficiency of a lysosomal enzyme activity that results in the progressive accumulation of the enzyme's undegraded substrates. Since lysosomal enzymes are expressed ubiquitously, many organ systems are often affected. Generally, the pathophysiology of a particular disorder is related to the degree of substrate accumulation in a cell or tissue type — determined by substrate synthesis and degradation rates — and the sensitivity of the cell or tissue type to the stored substrate. A case in point is metachromatic leukodystrophy (MLD), which is caused by the absence of arylsulfatase A. A major substrate for the enzyme is galactosyl-3-sulfate ceramide (sulfatide), a component of myelin sheaths produced by oligodendrocytes in the central nervous system and Schwann cells in the peripheral nervous system. In MLD, damage to oligodendrocytes and Schwann cells caused by storage of sulfatide results in demyelination, degeneration of the nervous system, and, in the most severe cases, death in childhood.
Neurodegeneration, a feature that MLD shares with the majority of lysosomal storage diseases, has made treatment of these diseases exceedingly difficult. Enzyme replacement therapies have been successful in preventing or reversing the somatic manifestations of some disorders by taking advantage of the cell's efficient receptor-mediated uptake systems (2, 3). Lysosomal enzymes carry oligosaccharide structures that enable their recognition by plasma membrane receptors, which deliver the enzymes to lysosomes. Thus far, enzyme replacement therapy has proven unsuitable for treatment of the nervous system in storage diseases, because the blood-brain barrier precludes entry of proteins administered systemically. To circumvent this obstacle, strategies are being attempted that include direct introduction of gene transfer vectors or genetically modified cells into the nervous system (4–6). It is uncertain if such a highly invasive strategy would be suitable for the persistent and widespread correction needed for a globally affected nervous system found in many of the storage diseases. Another strategy utilizes small molecules that can pass through the blood-brain barrier to either partially inhibit substrate synthesis or stabilize the mutant enzyme (7, 8). While promising in concept, these approaches are in early stages.


Transplantation of hematopoietic stem cells, from either bone marrow or cord blood, has been utilized over the past several years as a potential treatment for lysosomal storage diseases. Significantly, it is the only treatment to date that has been shown to prevent or retard neurodegeneration in storage disease patients (9). A study in this issue of the JCI by Biffi et al. (10) reinforces the concept that hematopoietic stem cell transplantation, as a therapeutic platform, has several features well-suited for the treatment of a globally affected nervous system in lysosomal storage diseases. The authors show, in a mouse model of MLD, that transplantation of hematopoietic stem cells transduced with lentiviral vectors carrying arylsulfatase A prevents neurologic disease as determined by the absence of sulfatide storage and neuropathology, and the preservation of neurologic function. Importantly, a global correction was achieved that included both the central and the peripheral nervous systems. Although hematopoietic stem cells can potentially differentiate into multiple nervous system cell types (11–14), in this study the repopulating cells were almost exclusively macrophages and microglia. Because donor cells that were engineered to produce high levels of arylsulfatase A were more effective at preventing neurodegeneration than wild-type cells, therapeutic improvement was likely achieved by enzyme-deficient cells capturing arylsulfatase A secreted by donor microglia and endoneural macrophages.


The findings in this study (10) help clarify a damage-response mechanism relevant to the pathogenesis of lysosomal storage diseases and illustrate how it can be exploited for nervous system therapy (Figure 1). Microglia, resident macrophages of the brain, are continuously replenished by blood-borne precursors, which cross the blood-brain barrier and migrate into the parenchyma of the nervous system. They take up residence as resting microglia to surveil and defend the nervous system against damaging agents or conditions. When the nervous system is injured, as in MLD (10), a damage-response mechanism is activated that results in the enhanced recruitment of macrophages/microglia. Most significantly, there is preferential recruitment of macrophages/microglia to sites of substrate storage and pathology (10, 14). Thus, if the hematopoietic stem cells have been corrected for the lysosomal enzyme deficiency, the macrophages/microglia may be able to deliver enzyme directly to sites of damage.
The vigorous process of recruiting macrophages/microglia into the nervous system and their subsequent activation may actually hasten neurodegeneration in lysosomal storage diseases. Studies utilizing a mouse model of Sandhoff disease, another sphingolipid storage disease exhibiting profound neurodegeneration, have shown that the population of activated macrophages/microglia expands considerably in the central nervous system prior to neuronal apoptosis (15). Intriguingly, the transplantation of these mice with bone marrow–containing hematopoietic stem cells substantially reduces macrophage/microglia activation and neuronal cell death without reducing substrate storage. Furthermore, blocking monocyte recruitment into the nervous system reduces neuronal cell death (Y.-P. Wu and R.L. Proia, unpublished data). These results indicate that the activated macrophages/microglia can trigger cell death possibly through the elaboration of cytotoxic, inflammatory mediators as has been suggested for other neurodegenerative conditions like Alzheimer disease.
The work by Biffi et al. (10) highlights the concept that therapeutic hematopoietic stem cell transplantation actually corrects a nervous system damage-response pathway defective in lysosomal storage disorders. Ex vivo genetic modification of hematopoietic stem cells to heighten expression of the missing enzyme in macrophages/microglia serves to restore and enhance the corrective potential of this pathway and to dampen its destructive capacity. Harnessed for therapy, the damage-response pathway appears unique in its capacity to afford widespread and persistent correction of a globally damaged nervous system as well as to target specifically affected areas. The approach taken by Biffi et al. (10), with its remarkable therapeutic effect on MLD, is particularly important because it outlines a strategy that may ultimately herald effective treatment of the nervous system in lysosomal storage diseases.

ninie

je sais que c'est long mais c'est vraiment un travaille important pour moi..
ps: merci Nico pour se que tu fais